API
< Back to all clusters
[HEALTH] · Spain, Poland, Pakistan, Brazil, Denmark · 7 sources

started · updated

GLP-1 medications face scrutiny over health risks and economic impacts

The rising popularity of GLP-1 receptor agonists, such as Ozempic, Wegovy, and Mounjaro, is driving significant medical, social, and economic shifts. While effective for treating type 2 diabetes and obesity, these drugs are associated with various side effects, including gastrointestinal issues like nausea and vomiting, potential loss of muscle mass, and risks of pancreatitis or kidney problems. Recent studies have also raised concerns regarding pregnancy, with research suggesting a possible link between semaglutide use for diabetes and increased risks of preterm birth.

Beyond clinical concerns, the widespread use of these medications is impacting global markets. Analysts note that reduced food consumption among users could decrease demand for sugar and processed goods, potentially affecting the agricultural sector. In Pakistan, the surge in demand for these treatments is notable due to high diabetes rates, leading to the production of cheaper local versions. Meanwhile, some cultural commentators view the trend of using weight-loss injections as a new form of luxury status symbol centered on self-optimization and controlled abstinence.

Entities

Copenhagen University Hospital Hvidovre · Eli Lilly · Henriette Svarre Nielsen · Human Reproduction Open · Mounjaro · Novo Nordisk · Ozempic · Wegovy